Milestone Pharmaceuticals Inc. MIST

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
37/100
Developing

Ranked against 712 peers in Biotechnology

About Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation … Full MIST analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.80), suggesting sticky customer base.
  • Strong Liquidity Buffer Liquidity position is strong (score 0.72), providing operational cushion.

Key risks

  • Below-Peer Operating Efficiency Operating margin at 25.8th percentile indicates below-peer efficiency.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.24), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
33
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where MIST ranks in Biotechnology

Milestone Pharmaceuticals Inc. ranks #404 of 713 scored companies in Biotechnology by moat score — the top 57%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
400 Rani Therapeutics Holdings, Inc RANI 38/100 Developing
401 Pasithea Therapeutics Corp. KTTA 38/100 Developing
402 Pasithea Therapeutics Corp. Warrant KTTAW 38/100 Developing
403 Matinas Biopharma Holdings, Inc MTNB 37/100 Developing
404 Milestone Pharmaceuticals Inc. MIST 37/100 Developing
405 Omeros Corporation OMER 37/100 Developing
406 Taysha Gene Therapies, Inc. TSHA 37/100 Developing
407 Boundless Bio, Inc. BOLD 37/100 Developing
408 CAMP4 THERAPEUTICS CORPORATION CAMP 37/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How MIST scores on the Corporate Default defenses

Pricing Power

Score 32 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 20 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 47 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 23 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 60 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 44 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding MIST's moat

What is Milestone Pharmaceuticals Inc.'s moat score?

Milestone Pharmaceuticals Inc. (MIST) scores 37 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #404 of 713 scored companies in Biotechnology, the top 57%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (60/100) and its weakest is Cost Advantage (20/100).

How does Milestone Pharmaceuticals Inc. compare with other Biotechnology companies?

Milestone Pharmaceuticals Inc. ranks #404 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Matinas Biopharma Holdings, Inc (MTNB) at 37 just above it and Omeros Corporation (OMER) at 37 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Milestone Pharmaceuticals Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Milestone Pharmaceuticals Inc.?

The Corporate Default template measures 6 defenses, and MIST scores: Pricing Power (32), Cost Advantage (20), Customer Stickiness (47), Capital Efficiency (23), Resilience (60), Scale & Market Position (44). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000